Please login to the form below

Alecensa

This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Lorbrena is also an important follow-up to Pfizer’s older ALK inhibitor Xalkori, which has come under pressure as it faces increasing competition from Roche’s Alecensa (alectinib) and Novartis’

Latest news

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

Sales of Xalkori have come under pressure recently as it faces increasing pressure from Roche’s Alecensa (alectinib) and Novartis’ Zykadia (ceritinib), with both therapies having previously bested Pfizer’s ... Although Lorbrena will face extreme
Roche reports continued growth in Q3, despite biosimilar competition

In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.
Pfizer’s Talzenna cleared for breast cancer in Europe

Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).
Pfizer gets EU nod for Tagrisso rival Vizimpro

Roche’s Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).
Pfizer claims rapid FDA nod for Lorbrena

Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa and Novartis’ Zykadia.